The use of an ultrasound device along with tissue plasminogen activator (tPA) is safe, based on the results of a phase II trial published online Oct. 24 in Stroke.

Boston Scientific completed its acquisition of Bard EP, the electrophysiology unit of C.R. Bard. 

The U.S. Department of Justice (DoJ) is investigating the PLATO clinical trial, Astra Zeneca announced in a financial report.

Digoxin has long been a mainstay in the treatment of systolic heart failure (HF). Recently, however, some studies have called its safety into question after finding the use of the drug in contemporary practice was associated with higher mortality rates.

SAN FRANCISCO—Two third-generation polymer-based drug-eluting stents performed comparably in DUTCH PEERS (TWENTE II), an all-comers trial that compared the flexible-design stents. The results were presented Oct. 31 at the Transcatheter Cardiovascular Therapeutics scientific session in San Francisco

High-risk patients who need aortic valve replacements (AVR) with or without CABG may benefit from hospitals that perform a high volume of these procedures, according to a study published in the November issue of Annals of Thoracic Surgery.

SAN FRANCISCO—Some patients implanted with a newer generation drug-eluting stent (DES) may safely discontinue dual antiplatelet therapy (DAPT) at three months, results from the OPTIMIZE trial presented Oct. 31 at the Transcatheter Cardiovascular Therapeutics (TCT) scientific session in San Francisco showed. 

In case you missed it, here is our previous coverage from TCT.